Results 181 to 190 of about 41,944 (264)

BRCA1/2 Reversion Mutations in Japanese Patients with Metastatic Breast Cancer Progressing on Olaparib: OLIVE (WJOG15321B). [PDF]

Breast Cancer
Sakai H, Kusumoto-Matsuo R, Hosonaga M, Nozawa K, Futamura M, Tanabe Y, Mukohara T, Shiraishi K, Toyama T, Yasojima H, Watanabe N, Sakai H, Iwasa T, Takeuchi N, Tada H, Sakai K, Chiba N, Takano T, Tsurutani J.   +18 more
europepmc   +1 more source

Plain language summary of results from the DUO-E study: durvalumab given with or without olaparib in patients with advanced endometrial cancer. [PDF]

Future Oncol
Westin SN, Moore K, Chon HS, Lee JY, Thomes Pepin J, Sundborg M, Shai A, de la Garza J, Nishio S, Gold MA, Wang K, McIntyre K, Tillmanns TD, Blank SV, Liu JH, McCollum M, Contreras Mejia F, Nishikawa T, Pennington K, Novak Z, De Melou AC, Sehouli J, Klasa-Mazurkiewicz D, Papadimitriou C, Gil-Martin M, Brasiuniene B, Donnelly C, Liu X, Nieuwenhuysen EV, DUO-E Investigators.   +29 more
europepmc   +1 more source

Efficacy of subsequent chemotherapy for patients with BRCA1/2-mutated recurrent epithelial ovarian cancer progressing on olaparib versus placebo maintenance: post-hoc analyses of the SOLO2/ENGOT Ov-21 trial.

Annals of Oncology, 2022
J. Frenel, J. Kim, N. Aryal, R. Asher, D. Berton, L. Vidal, P. Pautier, J. Ledermann, R. Penson, A. Oza, J. Korach, T. Huzarski, S. Pignata, N. Colombo, T. Park-Simon, K. Tamura, G. Sonke, A. Freimund, C. Lee, E. Pujade-Lauraine   +19 more
semanticscholar   +1 more source

Development and Validation of an SPE-LC-MS Method for the Determination of Epirubicin, Olaparib and Ribociclib in Human Serum. [PDF]

Biomedicines
Popescu MDE, Manda CV, Croitoru O, Calucică DM, Neamțu J, Biță A, Găman AM, Neamțu SD.   +7 more
europepmc   +1 more source

Repression of EGFR by new biguanide 4C potentiated ovarian cancer to PARP inhibitors through down-regulation of BRCA2 and Rad51. [PDF]

Cell Death Dis
Xiao D, Yao J, Yang X, Xie Y, Zhou X, Li D, Peng M, Wang W, Zou H, Yang X.   +9 more
europepmc   +1 more source

Genomic landscape and clinical impact of BRCA1/2 pathogenic variants in metastatic castration-resistant prostate cancer. [PDF]

NPJ Precis Oncol
Iida K, Urabe F, Matsui Y, Tashiro K, Yoshihara K, Urabe Y, Ishikawa T, Matsuzaki J, Kimura T, Saito Y.   +9 more
europepmc   +1 more source

Mitochondrial superoxide sustains a senescence-like phenotype in PARP- inhibited ovarian cancer cells by stabilizing HIF1α. [PDF]

Redox Biol
Yang T, Bu W, Xue X, Wu X, Zhou Y, Chen Y, Li Y, Zhang J, Li P, Shen F, Shi Y, Shao C.   +11 more
europepmc   +1 more source

Cleavage and inactivation of poly(ADP-ribose) polymerase in peripheral blood mononuclear cells of patients with acute respiratory distress syndrome. [PDF]

Respir Res
Santos SS, Ascenção K, Zuhra K, Martins V, Leite GGF, de Oliveira Cavalcanti Peres Rodrigues L, Hayashi JY, Brunialti MKC, Pecze L, Liaudet L, Vukovic J, Sridharan G, Salomão R, Szabo C.   +13 more
europepmc   +1 more source

FASN Inhibition Enhances the Efficacy of Chemotherapy in Colorectal Cancer by Inhibiting the DNA Damage Response. [PDF]

Cancer Res
Banerjee M, Zaytseva YY, Reusch EM, Napier DL, Hasani S, Rychahou P, Izumi T, Cheek DA, Li J, Flight RM, Moseley HNB, Weiss HL, McCulloch W, Evers BM, Gao T.   +14 more
europepmc   +1 more source

Implementation of a lifestyle‐based clinical pathway in daily clinical practice in men undergoing androgen deprivation therapy for prostate cancer [PDF]

, 2019
Bruggeman, Anniek, Bultijnck, Renée, De Muynck, Martine, Decaestecker, Karel, Deforche, Benedicte, Fonteyne, Valerie, Lumen, Nicolaas, Mortier, Stefanie, Ost, Piet, Raes, Anneleen, Rammant, Elke, Van Ruymbeke, Barbara   +11 more
core   +1 more source